Vincristine
Tinues to be studied in trials. Interferon IFN ; -alpha has also been studied in follicular lymphoma both in combination with chemotherapy and as maintenance therapy, however neither progression-free survival nor overall survival were improved and IFNalpha was associated with increased toxicity.12 Relapsed follicular lymphoma Previous response to therapy is the most important factor in determining the next treatment. Generally, patients who relapse two years or more after treatment with alkylating agents chlorambucil or CVP ; will respond to further treatment with the same agents. Patients who relapse earlier may respond to singleagent or combination chemotherapy, biological agents or radiotherapy. Cyclophosphamide, doxorubicin, vincristine and prednisolone CHOP ; , or CHOP-like regimens have been shown to induce remissions of around 12 months in patients with relapsed follicular lymphoma. Fludarabine, as a single agent or in combination chemotherapy, may give response rates of around 3262 per cent and 90 per cent respectively. Clinical trials investigating treatment with rituximab in relapsed or refractory indolent.
Large interindividual variability in the extent of drug-induced activation of apoptotic parameters was observed between patients. For instance, prednisoloneinduced PS externalization after 42 hours ranged between -26% and 86% median: 27% ; . Figure 4 and Table 2 show for each individual drug highly significant inverse correlations between the LC50 and 1 ; the percentage of cells with PS externalization and 2 ; the percentage of cells with m depolarization. However, caspase-3 activation and PARP inactivation showed a less-consistent inverse correlation pattern with cellular drug resistance. A significant inverse correlation between cellular drug resistance and the percentage of cells with caspase-3 activation was observed for prednisolone rs 0.60, P 0.001 ; and L-asparaginase rs -0.46, P 0.01 ; but not for vincristine and daunorubicin.
Middot; your healthcare provider will store vincristine as directed by the manufacturer.
The rationale for selecting these drugs is due in part to the fact that liposomal formulations of doxorubicin and vincristine are being separately evaluated as components of drug combinations.
Vincristine and vinblastine are drugs used in conventional chemotherapy.
13. Siddiqi A, Foley RR, Britton KE, et al. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol. 2001; 55: 515521. Nilsson M, Bjorkman U, Ekholm R, Ericson LE. Iodide transport in primary cultured thyroid follicle cells: evidence of a TSH-regulated channel mediating iodide efflux selectively across the apical domain of the plasma membrane. Eur J Cell Biol. 1990; 52: 270 Nilsson M, Ericson LE. Effect of epidermal growth factor and phorbol ester on thyroid epithelial integrity. Exp Cell Res. 1995; 219: 626 Labarca C, Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem. 1980; 102: 344 International Commission on Radiation Units and Measurements. Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides. Appendix: report no. 32. Washington, DC: ICRU; 1979: 1 62. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999; 140: 3404 Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na I symporter: mechanism, stoichiometry, and specificity. J Biol Chem. 1997; 72: 27230 Nilsson M. Integrity of the occluding barrier in high-resistant thyroid follicular epithelium in culture. I. Dependence on extracellular Ca2 is polarized. Eur J Cell Biol. 1991; 56: 295307. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998; 39: 1546 Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med. 2000; 27: 15911597 and vinorelbine.
References 1. Ruffolo, R.R., Jr., Nichols, A.J., Stadel, J.M., and Hieble, J.P. 1993 ; Annu Rev Pharmacol Toxicol 32, 243-279 2. Sallinen, J., Link, R.E., Haapalinna, A., Viitamaa, T., Kulatunga, M., Kobilka, B.K., Macdonald, E., Pelto-Huikko, M., Leino, T., Barsh, G.S., and Scheinin, M. 1997 ; Mol.Pharmacol. 51, 36-46 3. Sallinen, J., Haapalinna, A., Viitamaa, T., Kobilka, B.K., and Scheinin, M. 1998 ; The Journal of Neuroscience 18, 3035-3042 4. Tanila, H., Mustonen, K., Sallinen, J., Scheinin, M., and Riekkinen, P., Jr. 1999 ; European Journal of Neuroscience 11, 599-603 5. Bjorklund, M., Sirvio, J., Puolivali, J., Sallinen, J., Jakala, P., Scheinin, M., Kobilka, B.K., and Riekkinen, P., Jr. 1998 ; Mol Pharmacol 54, 569-576 6. Kobilka, B.K., Matsui, H., Kobilka, T.S., Yang-Feng, T.L., Francke, U., Caron, G., Lefkowitz, R.J., and Regan, J.W. 1987 ; Science 238, 650-656 7. Lomasney, J.W., Lorenz, W., Allen, L.F., King, K., Regan, J.W., Yang-Feng, T.L., Caron, M.G., and Lefkowitz, R.J. 1994 ; Proc.Nat.Acad i. 87, 5094-5098 8. Regan, J.W., Kobilka, T.S., Yang-Feng, T.L., Caron, M.G., Lefkowitz, R.J., and Kobilka, B.K. 1988 ; Proc.Natl.Acad i., USA 85, 6301-6305 9. Hein, L., Altman, J.D., and Kobilka, B.K. 1999 ; Nature 402, 181-184.
Hence called sterile. In this context, we can refer to Meek 1962: 21-22 ; who has described such linkage concept from the Physiocrats' point of view. If the net product is increasing from year to year, the level of agricultural output and, therefore, the general level of economic activity will rise. An increasing net product means, in the first place, that the landowners will spend more on agricultural produce; they will also spend more on manufactured goods, and the makers of these goods, whose incomes are thus increased, will in their turn spend more on agricultural produce; thus the aggregate demand for agricultural produce will increase, output will be stimulated, the net product will increase further, and the general level of economic activity will rise progressively from year to year. An increasing net product means, in the second place, that more will be available for investment. The landowners will have more to spare for investment in improving their land; the agricultural entrepreneurs, in so far as they happen at the time to be sharing in the net product, will have more to spare for maintaining and expanding their fixed and working capital; thus aggregate investment in agriculture will increase, and once again output will be stimulated, the net product will increase further, and the general level of economic activity will rise progressively from year to year. The eventual result of this process will be the attainment of maximum level of output consistent with the state of the country's resources and the existing techniques. If the net product is decreasing from year to year, on the other hand, a cumulative downward trend in the and viracept.
The list includes: chloramphenicol chloromycetin ; cisplatin platinol ; dapsone disulfiram antabuse ; ethionamide trecator-sc ; glutethimide gold hydralazine iodoquinol yodoxin ; isoniazid nydrazid ; metronidazole flagyl ; nitrofurantoin macrodantin ; phenytoin dilantin ; ribavirin virazole ; vincristine oncovin ; several other drugs should be either avoided or taken with caution while on hivid therapy.
In glioblastomas histological grade 4, n 257 ; the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine ccnu ; orally instead of bcnu, combined with vincristine and procarbazine pcv ; versus no chemotherapy and viread.
Medication Therapy Protocols By Generic & Trade Names Protocol No. trimethoprim-sulfamethoxazole co-trimoxazole ; ticarcillin disodium clavulanate potassium Tigecycline trimetrexate glucuronate trovafloxacin See: fluoroquinolones ; Tygacil See: tigecycline ; valacyclovir HCl valganciclovir See: ganciclovir ; vancomycin hydrochloride Valtrex see: valacyclovir HCl ; Venofer See: iron surcrose ; Versed See: midazolam hydrochloride Visitide See: cidofovir ; Vfend See: Voriconazole ; Vincristine vinorelbine tartrate voriconazole Xopenex See: albuterol ; ziconotide zidovudine AZT ; Zofran See: ondansetron hydrochloride ; Zosyn See: Piperacillin Tazobactrim.
In researching vincristine i read there is 1 mg in every ml and vistaril.
Tion between the results of electron microscopy and x-ray scattering; the controlled circumstances of preparation procedure, data collection, and data analysis; and our use of physiological concentrations of monovalent salt. Our absolute values of fiber diameter are in good agreement with neutron scattering in solution Suau et al., 1979 ; . Furthermore, the fiber diameters are not sensitive to ionic strength, as indicated by the radius of gyration measurements of Suau et al. 1979 ; , and our x-ray measurements showing less than a 5% change in the Necturus fiber diameter between 75 and 150 mM monovalent salt unpublished data ; . Because of the lack of earlier evidence of fiber variations, most investigators have maintained that the solenoid and twisted-ribbon models require a fixed external geometry e.g., McGhee et al., 1983; Woodcock et al., 1984; Butler, 1984 ; . Not only is that constraint incorrect, but also unnecessary for the solenoid and twisted-ribbon models, which can accommodate variations in the diameter. Only the crossed-linker models are constrained to particular diameters and dependence of the diameters upon linker length. Although our diameter data agree with the very specific predictions of the crossed-linker models, they are not inconsistent with the less specific predictions of other helical models. The external geometry of fibers might also vary within a tissue, owing to the well-studied heterogeneities in linker length within a tissue Prunell and Kornberg, 1982 ; . This heterogeneity has structural consequences for all classes of chromatin models. We have indirect evidence of this effect in chicken erythrocyte chromatin, which has a heterogeneous linker length e.g. Compton, et al., 1976 ; and seems to have a heterogeneous diameter, as evidenced by a very weak 20 nm reflection. This heterogeneity in diameter and linker length ; might be related to the complexity of the very-lysine-rich histones of avian erythrocytes. Chicken erythrocytes have three major very-lysine-rich proteins as detected by SDS-polyacrylamide gel electroLeft-Handed Double Helical Chromatin Fibers.
Introduction The tectonic history of the Kamchatka Peninsula is dominated by continuous accumulation and amalgamation of terranes with different origins, which were delivered by convergence between the Pacific plate and in former times, the Kula plate against Eurasia Freitag, 2002 ; . The Kronotsky and Cape Kamchatka Peninsulas show that the collision of terranes and the resulting tectonics are still important for major parts of East-Kamchatka. While the collision of the Kronotsky Peninsula is sorely influenced by the convergence of the Pacific plate, the Cape Kamchatka Peninsula is affected by the collision of the Aleutian Arc with Kamchatka, what gives the opportunity to compare two different processes that resulted in the amalgamation of terranes to Kamchatka. Data, analyse methods & object of work In this work, neotectonic structures along the east coast of Kamchatka were analysed in detail. The study area includes the Kronotsky Peninsula, the Cape Kamchatka Peninsula and a part of the Kumroch Range that lies between them Fig. 2 ; . The available remote sensing data Landsat TM7, ASTER, SRTM ; were examined by the analysis of lineaments, terraces Fig. 1 ; , spectral properties and drainage networks all over the study areas. The analyse and vivelle.
On the basis of the presented information it is acceptable to consider that savings in weight packaging can be obtained by using stiff and thin materials, and sandwich foamed trays, using polymeric materials from renewable resources. Sainsbury's presently uses 2, 000 tonnes of rigid packaging, so that a conservatively estimated 15% saving is expected to correspond to 300 tonnes of reduction in the weight of packaging. The fact that material may be home compostable is expected to divert additionally a fraction of the remaining material from the landfill. If these results could be adopted by whole UK packaging sector than the saving would be 1900 tonnes based on a 16% share of stream ; . Major savings, in terms of waste reduction could be achieved if foamed materials could be used.
Capacity g ; * Readability g ; * Weighing mods * Repeatability st v ; g ; linearity g ; + ; : * Tar rang * Stablization line * sensitivity drift 10-30C ; * Opreating temp * Calibration * Display cm ; * Power supply * Platform size cm ; B ; Accessories All needed accessories 400 0.0001 g, Ib, oz, ib, oz, ct, dwt, tables 3 ; , ozt, gn, mommes 0.007 0.001 full capacity by subtraction 2.5 Sec 10ppm C0 500 to 104 F0 100 to 50C0 External Digital calibration LCD 1.5 high ; Ac adapter ; 100, 120, 220, Vac, 50 60 Hz 12.2 dia and voriconazole.
Buy cheap vincristine online
Dose-Intensive Phase 8 cycles alternate CVAD with MTX Ara-C; median 6.2mo PLUS CNS prophylaxis ; Days Cyclophosphamide 300mg m IV q12h x6 doses Mesna 300mg m2 CIV q12h x6 doses Vincristine 2mg IV d4, 11 ; Doxorubicin 50mg m2 IV d4 ; Decadron 40mg po d1-4, 11-14 ; HD-MTX 200mg m2 IV over 2hr, then 800mg m2 IV over 24h d1 Leucovorin 15mg q6h x8 * d3-4 ; Ara-C 3g m2 IV over2h q12h x4 d2, 3 ; Methylprednisolone 50mg IV q12h d1-3 xx xx xx x xxxx xx xx xxxx x x.
Cheap vincristine
MarqiboTM is sphingosomal encapsulated vincristine, the widely used generic chemotherapeutic agent used in combination therapy to treat several types of cancers. MarqiboTM offers a targeted, increased and sustained delivery of vincristine to tumor sites. Compared with free form vincristine, sphingosomal vincristine SV ; significantly reduces neurotoxicity while extending the circulation half-life by as much as 60-fold 12 minutes free-form vs. 12 hours SV ; 6. We believe Marqibo'sTM profile enables more aggressive dosing and strong efficacy in treatment; significant improvement in safety profile provided by Marqibo'sTM liposomal formulation; valuable therapeutic differentiation over unmodified vincristine which suffers from dose-limiting neurotoxicity ; . MarqiboTM provides clear therapeutic differentiation over conventional vincristine. While vincristine is used heavily in the R-CHOP regimen for front-line treatment of non-Hodgkin's lymphoma please see About Non-Hodgkin's Lymphoma section ; , unmodified vincristine suffers from serious, dose-limiting neurotoxicity, and the capped total dose of 2mg is generally viewed as sub-optimal. Since lower doses of vincristine are correlated with lower response rates in clinical trials, there does appear to be a dose-response relationship. MarqiboTM extends the half-life of vincristine, which improves the efficacy-to-toxicity ratio significantly. In several trials, the dose of MarqiboTM has been pushed to 4mg before dose-limiting neurotoxicities have appeared. The ability to dose MarqiboTM higher than unmodified vincristine could also suggest higher efficacy and vortex.
118 BAD SCIENCE - GOOD MONEY One especially successful opportunity to profit from the obese comes from tapping into the low-carbohydrate craze popularized by Dr. Robert Atkins, author of Dr. Atkins Revolution and other tomes on saturated fat and protein doping. An estimated one in four Americans are or have been on Atkins diets, leading to a surge in demand for low-carbohydrate foods and a corresponding boon for their purveyors. Snack companies like Carbolite Foods have seen their profits rise from 0, 000 in 1999 to a projected 0 million for 2004 Pennington, 2004 ; . To many seeking to lose pounds, eating a diet low in carbohydrates is the magic bullet, and it is not only the weight loss industry that has promoted this unhealthful regimen. In one of the most vacuous pieces of journalism to ever besmirch the New York Times, science writer Gary Taubes' "What If It's All Been a Big Fat Lie?" discards a half-century of epidemiology to suggest that "members of the American medical establishment . spend 30 years ridiculing Robert Atkins only to discover that the unrepentant Atkins was right all along emphasis added ; . they find that their very own dietary recommendations - eat less fat and more carbohydrate - are the cause emphasis added ; of the rampaging epidemic of obesity in American 2002 ; ." To label Dr. Robert Atkins and self-proclaimed "science writer" Gary Taubes crackpots would be unfair to the countless crackpots whose words and actions, despite promoting nonsense, are at least relatively innocuous. There is nothing innocuous about following the Atkins diet. And now, thanks to "science writer" Gary Taubes and his willing accomplice in the New York Times, sales of the Atkins diet books reportedly tripled in the month following the Taubes polemic, presumably leading to a run on bacon, sausage, and whole milk Squires, 2002 ; . Truth is, Americans have never come close to meeting the recommended percentage of total caloric intake from complex carbohydrates, estimated at from 60 to 70 percent of total calories, depending upon the objective, unaligned source this excludes recommendations from food industry sources, and from government sources edited and censored by food industry lobbying efforts ; . Today less than half of calories consumed by AHCMJ, Volume 1, 2005.
Research contact: Andrei Gudkov, PhD Research contact: Farrel Fort, PhD Print Lead Email Lead [Back to Top] Company: Epiphany Biosciences HQ Location: Financing Type: Amount Raised: Description: San Francisco, CA Private equity placement .00 million Epiphany raises million in a Series A financing. The funding will be used to advance the company's programs, which include the antiviral drug candidate Valomaciclovir EPB348 ; through Phase IIb clinical trials against shingles. Strategy: Epiphany Biosciences develops drugs that focus on systematic diseases of viral origin and vytorin.
411. SYNERGISTIC AUGMENTATION OF VINCRISTINEINDUCED CYTOTOXICITY BY PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR IN HUMAN MALIGNANT GLIOMA CELLS : EVIDENCE FOR THE INVOLVEMENT OF P38 AND ERK SIGNALING PATHWAY I. Pollack, D. Premkumar, J. Mathas, and B. Arnold; Neurosurgery, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA Microtubule-interfering agents MIAs ; , such as vincristine, are widely used for the treatment of cancer, and are included in many treatment regimens for childhood brain tumors. The anticancer properties of MIAs have been attributed in part to interference with microtubule assembly, impairment of mitosis, and cytoskeletal changes, with additional effects on mitogen-activated protein kinase signaling and caspase activation. Because malignant gliomas commonly have dysregulation of PI3K Akt signaling, which can promote cell survival and potentially limit the activity of such agents, we questioned whether PI3K inhibition with LY294002 could potentiate the efficacy of vincristine in a panel of glioma cell lines versus normal astrocytes. We therefore examined the effects of the LY294002 and vincristine, alone and in combination, on cell survival, signal transduction, and apoptosis in a series of malignant glioma cell lines versus normal astrocytes. Simultaneous exposure to these inhibitors significantly induced cell death and inhibited proliferation and clonogenicity of the glioma cell lines. Quantitative analysis revealed that enhancement by LY294002 of vincristine-induced cytotoxicity was synergistic, leading to pronounced caspase activation at concentrations that had no significant effects on control cells. The enhanced cytotoxicity of this combination was associated with significant activation of p38 MAPK signaling and induction of G2 M blockade on cell cycle analysis. Pretreatment with either SB203580 or z-VAD k, selective inhibitors of p38 MAPK and caspase signaling, respectively, abrogated the apoptotic response to the combination of LY294002 and vincristine. Taken together, these fi ndings demonstrate that PI3K Akt inhibition can potentiate the effects of vincristine and that the combination of molecularly targeted therapies and conventional agents could provide a potent strategy to treat patients with malignant gliomas.
To ensure broad sectoral representation in land and water use planning for merto cebu watersheds and abraxane and vincristine.
Buy vincristine online
These include drugs often used during chemotherapy, such as docetaxel taxotere ; , paclitaxel taxol ; , etoposide vepesid ; , irinotecan camptosar ; , ifosfamide ifex ; , imatinib gleevec ; , vinorelbine navelbine ; , vinblastine velban ; , vincristine oncovin ; , methylprednisolone, and dexamethasone decadron ; by mouth.
Middot; if for any reason an overdose of vincristine is suspected, seek emergency medical attention or contact your healthcare provider immediately and acamprosate.
Forest Laboratories, Inc.: Placebo-Controlled Evaluation of the Safety and Efficacy of Lu26-054 in the Prevention of Depression Relapse - CRO: Pope and Associates Forest Laboratories, Inc.: Flexible Dose Comparison of the Safety and Efficacy of Lu26-054 and Placebo in the Treatment of Generalized Anxiety Disorder - CRO: Pope and Associates Forest Laboratories, Inc.: Evaluation of the Saftey and Efficacy of Lu26-054 in the Prevention of Depression Recurrence - CRO: CICR, Inc. Forest Laboratories, Inc.: An Open-Label Extension Study of the Safety and Efficacy of Lu 26-054 in Patients with Generalized Anxiety Disorder - CRO: Pope and Associates.
Comments 0 ; 42 blinks blink it medlineplus drug information: vincristine systemic ; shared by ylinks on dec 19, 2005 via source url.
Colony-stimulating factor median, 42 pg per milliliter; range, 8 to 255 ; . All concentrations of cytokines including stem-cell factor, interleukin-1b, and interleukin-6 ; dropped to undetectable levels after the cultured cells were washed, suggesting that very small amounts!
Yes it can. Various mechanisms of drug resistance have been proposed based on studies of antibiotics; it may develop in an ini tially sensitive cell population through the stepwise induction of a resistant cell line, or it may be caused by regrowth of an inherently resistant population. If the latter mechanism exists in cancer cells, additional drugs may be required for each resistant cell line. The success of any chemotherapeutic program will therefore depend on the number of resistant lines in the tumor population and the number of available drugs which can be used in combination. This might account for the apparent success of many drug combinations in situations where single agents produced only temporary responses. For st mt lll ; iOt't'll .silperiOl to single agent them-a J ; v? The treatment of acute lymphatic leukemia of childhood is a good example. The complete remission rate has improved from 22 per cent with methotrexate alone to nearly 100 percent using two to four drugs in combination. At the National Cancer Institute, median survival in acute leukemia of childhood has improved from six months in 1956 when single agents were used prednisone, methotrexate and 6-mercaptopurine ; to 36 months in 1965 follow ing the development of as many as eight active drugs and their use in combination. Unfortunately, no agent is capable of permanently reverting all leukemic bone marrow to normal. In a controlled trial, the overall remission rates for 6-mercaptopurine and methotrexate used alone were 48 percent and 29 percent respectively, while the combination produced a 59 percent response and, more impor tantly, twice the percentage of complete remissions than either of the single agents. Furthermore, duration of remission after single agent treatment, without maintenance, was short, averaging 45 to 60 days. In a randomized trial comparing 6-mercaptopurine to monthly vincristine and prednisone as remission maintenance treatment, the median duration of remission was 16 weeks for the single agent, compared to over 33 weeks for the combination. I"las M'OPP regimen also increased survival over simigle the agent.
Inpatient treatment usually takes place in hospitals and rehabs, and provides: Detox, to clear you body of drugs. You will be given medication and medical help to make this less unpleasant Help with health problems linked to drug use such as liver problems ; Stabilisation on medication Urgent medical care and vinorelbine.
18. Lampidis, T. J., Bernal, S. D., Summerhayes, I. C., and Chen, L. B. Selective toxicity of rhodamine-123 in carcinoma cells in vitro. Cancer Res., 43: 716720, 1983. Lampidis, T. J., Munck, J. N., Bennoun, M., and Tapiero, H. A difference in mechanisms of resistance between Adriamycin ADM ; and rhodamine-123 Rho-123 ; in ADM-resistant Friend leukemia cells. Proc. Am. Assoc. Cancer Res. 25: 340.1984. 20. Lampidis, T. J., Salet, C., Moreno, G., and Chen, L. B. Effects of the mito chondrial probe rhodamine-123 and related analogs on the function and viability of pulsating myocardial cells in culture. Agents Actions, 14: 3-10, 1984. Meriwether, W. D., and Bachur, N. R. Inhibition of DNA and RNA metabolism by daunorubicin and Adriamycin in L1210 mouse leukemia. Cancer Res., 32: 1137-1142, 1972. Pigram, W. J., Fuller, W., and Hamilton, L. D. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nat. New Bid., 235: 17-19, 1972. Salmon, S. E., Hamburger, A. W., Soehnlen, B., Durie, B. G. M., Alberts, D. S., and Moon, T. E. Quantittenof differential sensitivity of human-tumor stem eels to anti-cancer drugs. N. Engl. J. Med., 298: 1321-1327, 1978. Skovsgaard, T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor eels. Cancer Res., 38: 1785-1791, 1978. Skovsgaard, T. Mechanisms of cross-resistance between vincristine and dau norubicin in Ehrlich asles tumor celts. Cancer Res., 38: 4722-4727, 1978. Summerhayes, I. C., Lampidis, T. J., Bemal, S. D., Nadakavukaren, J. J., Nadakavukaren, K. K., Shepherd, E. L., and Chen. L B. Unusual retention of rhodamine-123 by mitochondria in muscle and carcinoma cells. Proc. Nati. Acad. Sd. USA. 79: 5292-5296, 1982. Tapiero, H., Fourcade, A., and Bennoun, M. Comparative uptake of Adriamycin, daunorubicin and aclacinomycin-A in sensitive and resistant Friend leukemia eels. In: G. Mathe, R. Maral, and R. de Jager eds. ; , Anthracydines: Current Status and Future Developments, pp. 95-100. New York: Masson Publishing USA, Inc., 1983. 28. Tapiero, H., Fourcade, A., Goldschmidt, E., and Zwingelstein, G. Mechanisms of resistance to anthracydines. In: Current drugs and methods of cancer treatment, pp. 181-184. New York: Masson Publishing USA, Inc., 1983. 29. Tapiero, H., Fourcade, A., Vaigot, P., and Partii, J. J. Comparative uptake of Adriamycin and daunorubicin in sensitive and resistant Friend leukemia cells measured by flow cytometry. Cytometry, 2: 298-302, 1982. Thayer, W. S. Adriamycin stimulated Superoxide formation in submitochondrial particles. Chem.-Bid. Interact., 79: 265-278, 1977. Von Hoff, D. D., Casper, J., Bradley, E., Sanbach, J., Jones. D., and Makuch, R. Association between human tumor colony-forming assay results and re sponse of an individual patient's tumor to chemotherapy. Am. J. Med., 70: 1027-1032, 1981. Yesair, D. W., Thayer, P. S., McNitt, S., and Teague, K. Comparative uptake, metabolism and retention of anthracydines by tumor growing in vitro ana In vivo. Ear. J. Cancer, 76: 901-907, 1980.
Here the Duke is seen as a Promethean Romantic hero, as heir to the "I" of the Romantic poetry of experience. Moral judgement is only important "as the thing suspended, as a measure of the price we pay for the privilege of appreciating to the full this extraordinary man." Langbaum 1974, p. 77 ; . Philip Drew contradicts Langbaum's view. He sees Browning's poetry as "essentially a poetry which demands judgements of the reader and normally provides him with fairly plain hints as to what his judgement is expected to be." Drew 1970, p. 27 ; . He summarizes Langbaum's account of "My Last Duchess" and continues.
Mg123 m2 day 1, doxorubicin 40-60 mg m2 day 1, vincristine 2 mg day 1, and prednisone 200 mg per day for five days. Level I: Prednisone 100 mg day days 1-5 Approximately 2, 493 patients with NHL were treated with CHOP using a prednisone dose of 100 mg day days 1-5 as part of 21 different clinical trials. Two of the largest trials using this dose level are discussed below. The excellent results obtained in a previous pilot study by Gottlieb et al. [20] led to the first large, prospective, randomized trial SWOG trial 7204 ; , using the CHOP chemotherapy regimen for NHL CTX 750 mg m2 day 1, ADR 50 mg m2 day 1, VCR 1.4 mg m2 day 1, and prednisone 100 mg days 1-5 [25 mg po four times daily] ; , conducted between April 1972 and September 1974 [22]. This is the study that most textbooks and published clinical trials using the CHOP program refer to as the source for the standard CHOP regimen and the first trial that uses the name CHOP to identify this chemotherapy combination. Five hundred and six patients with stage III and IV NHL were entered in this study. Patients were randomly assigned between CHOP 246 eligible patients 204 evaluable patients ; and HOP ADR, VCR, and prednisone patients in complete remission after consolidation chemotherapy were then randomized to a maintenance chemotherapy program with either COP CTX, VCR, and prednisone ; or OAP VCR, ARA-C, and prednisone ; . One of the most important prospective clinical trials for patients with NHL was the national high-priority lymphoma study Intergroup 0067; SWOG 8516; ECOG 3487 ; conducted between April 4, 1986, and June 15, 1991 [23]. In this study, 1, 138 previously untreated patients with advanced disease were registered and 899 were found eligible. CHOP regimen with prednisone at 100 mg day days 1-5 225 patients ; was compared with the newer and more aggressive chemotherapy regimens known as m-BACOD methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone ; , ProMace-CytaBOM prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, and bleomycin ; , and MACOP-B methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone ; . There has been no statistically significant difference in overall response rate, time to treatment failure, or overall survival among these four regimens. The CHOP regimen proved to be less toxic and less expensive. This study established CHOP as the gold standard for the treatment of NHL, and the regimen used as the benchmark for all new treatments. The comparative analyses of these and the remainder of clinical trials using a CHOP regimen with prednisone at 100 mg daily for five days are summarized in Table 2.
ABMTR Autologous Blood and Marrow Transplant Registry; autoSCT autologous stem cell transplantation; CHOP cyclophosphamide, hydroxydaunomycin doxorubicin ; , vincristine Oncovin ; and prednisone; CLL chronic lymphocytic leukemia; DFS disease-free survival; EBMTR European Bone Marrow Transplant Registry; EFS eventfree survival; F fludarabine; FC fludarabine and cyclophosphamide; GCLLSG German CLL Study Group; GOELAMS Groupe Ouest Est d'etude des Leucemies et Autres Maladies du Sang; IBMTR International Bone Marrow Transplant Registry; MRC Medical Research Council; NR not reported; NS not specified; OS overall survival; PFS progression-free survival; TRM treatment-related mortality. 117 patients enrolled only 65 proceeded to autoSCT ; . Proportion of chemotherapy-naive patients not specified. CHOP F vs autoSCT. Of 41 patients, 28 underwent autoSCT. There were 142 patients. 48 patients in CR after miniChOP and F ; randomized to autoSCT or observation, whereas 52 patients not in CR randomized to autoSCT or FC. #CD34 selection performed in 15 of patients. * There were 325 patients of which 83 underwent autoSCT ; . There were 128 of which 86% were chemotherapy-naive at study entry only 98 proceeded to autoSCT ; . At least 41 patients had no prior therapy.
|